Our Research Team
Group Leader Pre-Clinical
David received his BSc(Hons) in Microbiology from the University of Manchester, additionally working for Boehringer-Ingelheim’s Metabolic Disease arm in Germany to investigate the role of dyslipidaemia in cancer. Following-on from his D.Phil. in Clinical Medicine at the University of Oxford, David additionally completed postdoctoral work funded from his initial findings, focusing on the mechanisms of immune cell trafficking through the lymphatic system.
More recently, David moved into biotech, progressing several TCR-based immunotherapies through to IND approval for evaluation in clinical trials. In addition to working on, and leading various investigative pipeline projects at Adaptimmune, he provided data integrity and compliance assurance management, overhauling aspects of the company’s Laboratory Information Management System (LIMS).
However, David is now keen to draw further on his previous training in Immunology. It is his belief that there are clear parallels between the strategies exploited during tumour metastasis and conversely during successful T-cell infiltration of solid tumours. David is keen to explore this, and other such mechanisms further, as guided by investigations into the Long-Term Survivor cohort, in a bid to advance Continuum’s commitment to address any unmet clinical need for Cancer patients.
In terms of activities outside of the lab, David has a keen interest in classic cars, generally seeking-out splendid things and spending time with his dog. He may even consider another hound at some point!